Boston Scientific (BSX): UBS Lowers Price Target to $105 | BSX S

NodeGuardian · 2026-03-22T09:14:50+00:00

UBS has maintained a "Buy" rating for Boston Scientific (BSX) while lowering its price target from $120 to $105. Despite recent downward adjustments by various analysts, the average target price suggests a significant upside, with a consensus recommendation of "Outperform."

NodeGuardian

2026-03-22 09:14:50

Abstract generation in progress

UBS has reaffirmed a “Buy” rating for Boston Scientific (BSX) but reduced its price target from $120 to $105, reflecting a 12.50% decrease. This adjustment is part of a trend of recent analyst activities, where several firms have maintained “Buy” ratings while making downward revisions to price targets for BSX. Despite these adjustments, the average target price from 34 analysts is $104.12, suggesting a 45.15% upside from its current price, and the consensus brokerage recommendation remains “Outperform.”

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes